A5020093408- Autoimmune Bullous Skin Diseases
- Urticaria and Related Conditions
- Systemic Lupus Erythematosus Research
- Autoimmune and Inflammatory Disorders
- Dermatology and Skin Diseases
- Dermatological and COVID-19 studies
- Peripheral Neuropathies and Disorders
- Psoriasis: Treatment and Pathogenesis
- Skin Diseases and Diabetes
- Eosinophilic Disorders and Syndromes
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Drug-Induced Adverse Reactions
- Heparin-Induced Thrombocytopenia and Thrombosis
- Drug-Induced Ocular Toxicity
- Skin and Cellular Biology Research
- Lymphadenopathy Diagnosis and Analysis
- Muscle and Compartmental Disorders
- Oral Health Pathology and Treatment
- Food Allergy and Anaphylaxis Research
- Syphilis Diagnosis and Treatment
- Polyomavirus and related diseases
- Dermatological and Skeletal Disorders
- Viral Infections and Immunology Research
- Inflammatory Myopathies and Dermatomyositis
- Leprosy Research and Treatment
University of Florence
2022-2025
Azienda Usl Toscana Centro
2024
University of Pavia
2021
The association between psoriasis and streptococcal infection has been widely explored in both children adults. However, the exact impact of Streptococcus pharyngeal on course is not fully comprehended. This study investigated effectiveness systemic antibiotic therapy conjunction with standard topical treatment for psoriatic patients concomitant throat infection. research involved 115 mild-to-moderate psoriasis, clinically assessed using Psoriasis Area Severity Index (PASI). Patients active...
Purpose Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment moderate-to-severe plaque psoriasis in two dosages. We conducted 16-week multicenter retrospective study to compare effectiveness and safety tildrakizumab 200 mg versus 100 patients with high disease burden or body weight.
The pandemic outbreak of Coronavirus Disease 2019 (COVID-19) led to the development mRNA vaccines. With extensive vaccination campaign performed worldwide, many adverse reactions these drugs have been reported in literature. Although most them are mild and self-limiting, they may sometimes cause psychological stress require efforts make a differential diagnosis with other conditions. This is case lymphadenopathies lymphedema patients history cancer. Herein we present arm developed ten days...
The article presents an adverse event that occurred after the induction phase of dupilumab, administered in another country to a patient affected by bullous pemphigoid.
Introduction Pemphigus encompasses a group of muco-cutaneous autoimmune bullous diseases characterized by the loss adhesion between keratinocytes. The disease is associated with increased morbidity and mortality. Materials Methods We clinical patterns, survival, comorbidities, drug prescriptions in patients pemphigus referred to Section Dermatology University Florence from January 2010 December 2021. Results A total 149 were identified (female/male sex ratio = 2.0). Median age at diagnosis...
Bullous Pemphigoid (BP) is a common autoimmune blistering disorder with unknown aetiology. During the last decades, its association various comorbidities, including cardiovascular, metabolic, neuropsychiatric, and neoplastic disorders, has been established. However, in recent years an increasing number of BP cases have also reported rarer diseases, Acquired Reactive Perforating Collagenosis (ARPC). Patients coexisting ARPC to share clinical features metabolic comorbidities e.g., Diabetes...
It is well known that viral infections play a relevant role in inducing or protecting from autoimmune diseases, thus representing major environmental factor the disruption of immune system genetically susceptible individuals. Since beginning Covid-19 pandemic great number clinical and epidemiological studies have demonstrated SARS-CoV-2 infection no exception to rule by interfering on many different levels normal functioning our system. Even though growing case series reports has been cited...
The clinical syndrome characterized by an acute mucositis, with variable involvement of the oral, ocular, and genital mucosa minimal or absent skin involvement, has been described as "atypical Stevens-Johnson syndrome," "Stevens-Johnson without lesions," "Fuchs syndrome." In past few years, a new nomenclature was introduced, mostly focused on etiologic agent, Mycoplasma pneumoniae, including terms such "Mycoplasma pneumoniae–associated mucositis"1,2 "Mycoplasma-induced rash mucositis"3; more...
Lupus erythematosus tumidus (LET) is a subset of cutaneous lupus that generally presents with urticaria-like papules and plaques located on sun-exposed areas. Systemic treatment antimalarials, especially hydroxychloroquine (HCQ), the first-line systemic therapy for LET. Even if these drugs have safe profile, side effects such as retinal toxicity, maculopapular rash, gastrointestinal upset, hemolytic anemia blue-gray discoloration skin or mucous membranes, been rarely reported in literature....
OPINION article Front. Med., 01 December 2022Sec. Dermatology Volume 9 - 2022 | https://doi.org/10.3389/fmed.2022.1081063